Bayer is paying Arvinas $17.5 million upfront to develop protein-degrading treatments for cardiovascular, oncological and gynecological diseases. The partners will apply Arvinas’ targeted protein degrader technology to targets selected by Bayer.
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2024,